ClinicalTrials.gg
CompletedNCT02962648FERWON-EXTUpdated Mar 10, 2020Results posted

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose in Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
20th of 32
103 · median 121
Started
2017
with 4 others
Phase 3
18 of 32
4 open now
Registered
11th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 20th largest by enrollment, is one of 5 that started in 2017, is one of 18 in phase 3, and was the 11th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.

Read the detailed description

Among the various formulations of parenteral iron that are currently available, iron isomaltoside/ferric derisomaltose may allow flexibility in terms of high and rapid dosing. Up to now, most clinical trials with intravenous (IV) iron treatment were of 4-12 weeks in duration; longer trials are warranted to follow-up on long-term safety.

The aim of the trial was to evaluate the safety and efficacy of IV iron isomaltoside/ferric derisomaltose re-dosing in subjects who were previously treated with iron isomaltoside/ferric derisomaltose in lead-in trials.

This was a 6-months extension trial lasting 26 weeks. Eligible subjects attended 5 visits: screening, baseline (subjects treated with a single IV dose of 1000 mg iron isomaltoside/ferric derisomaltose), and follow-up visits at week 2, 13, and 26 weeks after the IV dose, for safety and efficacy assessments.

03

Conditions studied

  • Iron Deficiency Anemia
  • Iron Deficiency Anaemia

Keywords

  • Iron Deficiency Anemia
  • Iron Deficiency Anaemia
  • IDA
  • Intravenous iron replacement therapy
  • Chronic Kidney Disease
  • CKD
  • Iron isomaltoside
  • Ferric derisomaltose
  • Monofer
  • Monoferric
  • Monover
  • Monofar
  • Monoferro
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed one of the lead-in trials
  2. Randomised and dosed with iron isomaltoside/ferric derisomaltose in one of the lead-in trials.
  3. (Hb) of ≤ 11 g/dL
  4. Screening serum ferritin (s-ferritin) ≤ 100 ng/mL, or ≤ 300 ng/mL if transferrin saturation (TSAT) ≤ 30 %
  5. Willingness to participate and signing the form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Intravenous (IV) iron treatment between the lead-in trial and screening
  2. During 30-day period prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy
  3. Received an drug within 30 days of screening
  4. Decompensated liver cirrhosis or active hepatitis
  5. Pregnant or nursing women.
  6. Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside/ferric derisomaltose

    Administered IV

    Drug: Iron isomaltoside/ferric derisomaltose

Interventions

  • DrugIron isomaltoside/ferric derisomaltose

    Drug page: Iron isomaltoside 1000

    Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.

    Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Drug Reactions (ADR)

    Safety Evaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product.

    Time frame: Baseline to week 26

Secondary outcomes

  1. Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

    Safety. For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity terms that were included in the analysis were those that started or after the first dose of treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: Loss of consciousness; Seizure; Syncope; Unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.

    Time frame: Baseline to week 26

  2. Composite Cardiovascular Adverse Events (AEs)

    Safety Results show the composite cardiovascular AEs, that started on or after the first dose of treatment (i.e. treatment emergent) up to month 6. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.

    Time frame: Baseline to week 26

  3. Time to First Composite Cardiovascular Safety AE

    Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the Clinical Endpoint Adjudication Committee (CEAC), were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.

    Time frame: Baseline, week 2, 13, and 26

  4. S-phosphate <2 mg/dL at Any Time From Baseline to Week 26

    Safety Results show the number of trial participants and their status of s-phosphate \<2 mg/dL, at any time from baseline to week 26.

    Time frame: Baseline to week 26

  5. Change in Hb From Baseline to Week 2, 13, and 26

    Efficacy. Change in Hb from baseline to week 2, 13, and 26.

    Time frame: Baseline, week 2, 13, and 26

  6. Change in S-ferritin From Baseline to Week 2, 13, and 26

    Efficacy. Change in s-ferritin from baseline to week 2, 13, and 26.

    Time frame: Baseline, week 2, 13, and 26

  7. Change in Transferrin Saturation (TSAT) From Baseline to Week 2, 13, and 26

    Efficacy Change in transferrin saturation (TSAT) from baseline to week 2, 13, and 26. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.

    Time frame: Baseline, week 2, 13, and 26

  8. Change in S-iron From Baseline to Week 2, 13, and 26

    Efficacy. Change in s-iron from baseline to week 2, 13, and 26.

    Time frame: Baseline, week 2, 13, and 26

07

Results

Posted Mar 10, 2020

Participant flow

A total of 193 subjects were screened and 103 subjects were enrolled into the trial.

Participant flow — Overall Study
MilestoneIron Isomaltoside/Ferric Derisomaltose
Started103
Completed94
Not completed9
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up3
Withdrew: Physician decision1
Withdrew: Subject had problems with transportation2

Outcome measures

PrimaryNumber of Subjects With Adverse Drug Reactions (ADR)

Safety Evaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product.

Time frame:
Baseline to week 26
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Drug Reactions (ADR)
ParticipantsIron Isomaltoside/Ferric Derisomaltose
Number of Subjects With Adverse Drug Reactions (ADR)5
SecondaryIncidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

Safety. For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity terms that were included in the analysis were those that started or after the first dose of treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: Loss of consciousness; Seizure; Syncope; Unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.

Time frame:
Baseline to week 26
Reported as:
Count of participants · Participants
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
ParticipantsIron Isomaltoside/Ferric Derisomaltose
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions0
SecondaryComposite Cardiovascular Adverse Events (AEs)

Safety Results show the composite cardiovascular AEs, that started on or after the first dose of treatment (i.e. treatment emergent) up to month 6. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following: * Death due to any cause * Non-fatal myocardial infarction * Non-fatal stroke * Unstable angina requiring hospitalisation * Congestive heart failure requiring hospitalisation or medical intervention * Arrhythmias * Hypertension * Hypotension Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.

Time frame:
Baseline to week 26
Reported as:
Count of participants · Participants
Composite Cardiovascular Adverse Events (AEs)
ParticipantsIron Isomaltoside/Ferric Derisomaltose
Composite Cardiovascular Adverse Events (AEs)6
SecondaryTime to First Composite Cardiovascular Safety AE

Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the Clinical Endpoint Adjudication Committee (CEAC), were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.

Time frame:
Baseline, week 2, 13, and 26
Reported as:
Median · week
Time to First Composite Cardiovascular Safety AE
weekIron Isomaltoside/Ferric Derisomaltose
Time to First Composite Cardiovascular Safety AENA (NA to NA)
SecondaryS-phosphate <2 mg/dL at Any Time From Baseline to Week 26

Safety Results show the number of trial participants and their status of s-phosphate \<2 mg/dL, at any time from baseline to week 26.

Time frame:
Baseline to week 26
Reported as:
Count of participants · Participants
S-phosphate <2 mg/dL at Any Time From Baseline to Week 26
ParticipantsIron Isomaltoside/Ferric Derisomaltose
Yes8
No94
SecondaryChange in Hb From Baseline to Week 2, 13, and 26

Efficacy. Change in Hb from baseline to week 2, 13, and 26.

Time frame:
Baseline, week 2, 13, and 26
Reported as:
Mean · g/dL
Change in Hb From Baseline to Week 2, 13, and 26
g/dLIron Isomaltoside/Ferric Derisomaltose
Week 21.23 ± 1.40
Week 131.73 ± 1.83
Week 261.34 ± 1.93
SecondaryChange in S-ferritin From Baseline to Week 2, 13, and 26

Efficacy. Change in s-ferritin from baseline to week 2, 13, and 26.

Time frame:
Baseline, week 2, 13, and 26
Reported as:
Mean · ng/mL
Change in S-ferritin From Baseline to Week 2, 13, and 26
ng/mLIron Isomaltoside/Ferric Derisomaltose
Week 2255.6 ± 177.9
Week 1387.9 ± 123.6
Week 2693.9 ± 180.4
SecondaryChange in Transferrin Saturation (TSAT) From Baseline to Week 2, 13, and 26

Efficacy Change in transferrin saturation (TSAT) from baseline to week 2, 13, and 26. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.

Time frame:
Baseline, week 2, 13, and 26
Reported as:
Mean · percentage of saturation
Change in Transferrin Saturation (TSAT) From Baseline to Week 2, 13, and 26
percentage of saturationIron Isomaltoside/Ferric Derisomaltose
Week 28.16 ± 11.87
Week 134.42 ± 10.81
Week 261.78 ± 10.63
SecondaryChange in S-iron From Baseline to Week 2, 13, and 26

Efficacy. Change in s-iron from baseline to week 2, 13, and 26.

Time frame:
Baseline, week 2, 13, and 26
Reported as:
Mean · μg/dL
Change in S-iron From Baseline to Week 2, 13, and 26
μg/dLIron Isomaltoside/Ferric Derisomaltose
Week 221.1 ± 50.5
Week 1310.7 ± 45.4
Week 264.0 ± 44.1

Adverse events

Collected over From the time subjects signed the informed consent form (CRF) until they completed the trial, all adverse events (AEs) or serious adverse events (SAEs) were recorded in the CRF. The actual study duration was 6 months (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 6.5 months (including a 14-day screening period).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside/Ferric Derisomaltose1/193 (0.5%)13/102 (12.7%)17/102 (16.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventIron Isomaltoside/Ferric Derisomaltose
Chronic kidney diseaseRenal and urinary disorders2/102
AppendicitisInfections and infestations1/102
CellulitisInfections and infestations1/102
EndometritisInfections and infestations1/102
Cardiac failure congestiveCardiac disorders1/102
Chest painGeneral disorders1/102
FallInjury, poisoning and procedural complications1/102
HypocalcaemiaMetabolism and nutrition disorders1/102
Neck painMusculoskeletal and connective tissue disorders1/102
MenorrhagiaReproductive system and breast disorders1/102
Most frequent other events
Most frequent other events
EventIron Isomaltoside/Ferric Derisomaltose
FatigueGeneral disorders3/102
Abdominal painGastrointestinal disorders3/102
Urinary tract infectionInfections and infestations3/102
DizzinessNervous system disorders3/102
HeadacheNervous system disorders3/102
HypertensionVascular disorders3/102
AnaemiaBlood and lymphatic system disorders3/102

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Iron Isomaltoside/Ferric Derisomaltose
<=18 years0
Between 18 and 65 years82
>=65 years21
Age, Continuous
Age, Continuous(years)Iron Isomaltoside/Ferric Derisomaltose
Mean49.9 ± 15.7
Age, Customized
Age, Customized(Participants)Iron Isomaltoside/Ferric Derisomaltose
18-64 years82
65-84 years18
>84 years3
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside/Ferric Derisomaltose
Female87
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Iron Isomaltoside/Ferric Derisomaltose
Hispanic or Latino46
Not Hispanic or Latino57
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Iron Isomaltoside/Ferric Derisomaltose
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American41
White60
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside/Ferric Derisomaltose
United States103
Current smoker
Current smoker(Participants)Iron Isomaltoside/Ferric Derisomaltose
Yes8
No95
08

Study locations

22 sites
  • Pharmacosmos Investigational Site
    Chula Vista, California 91910, United States
  • Pharmacosmos Investigational Site 1
    La Mesa, California 91942, United States
  • Pharmacosmos Investigational Site 2
    La Mesa, California 91942, United States
  • Pharmacosmos Investigational Site
    Northridge, California 91324, United States
  • Pharmacosmos Investigational Site
    Porterville, California 93257, United States
  • Pharmacosmos Investigational Site
    Doral, Florida 33172, United States
  • Pharmacosmos Investigational Site
    Hialeah, Florida 33012, United States
  • Pharmacosmos Investigational Site
    Miami Lakes, Florida 33014, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33135, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33147, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33165, United States
  • Pharmacosmos Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pharmacosmos Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Pharmacosmos Investigational Site
    Metairie, Louisiana 70006, United States
  • Pharmacosmos Investigational Site
    New Orleans, Louisiana 70125, United States
  • Pharmacosmos Investigational Site
    Shreveport, Louisiana 71101, United States
  • Pharmacosmos Investigational Site
    Plainsboro, New Jersey 08536, United States
  • Pharmacosmos Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Pharmacosmos Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Pharmacosmos Investigational Site
    Houston, Texas 77030, United States
  • Pharmacosmos Investigational Site 1
    San Antonio, Texas 78215, United States
  • Pharmacosmos Investigational Site 2
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2018, 17 months.

Results were first posted in Mar 2020, 1 year 8 months after primary completion. A results delay was requested in May 2019.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2016
First posted
Nov 11, 2016
StartActual
Jan 9, 2017
Primary completionActual
Jun 12, 2018
CompletionActual
Jun 12, 2018
Results delay requested
May 22, 2019
Results first posted
Mar 10, 2020
Last update
Mar 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02962648
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Nov 11, 2016
Start date
Jan 9, 2017
Primary completion
Jun 12, 2018
Completion
Jun 12, 2018
Results posted
Mar 10, 2020
Last update
Mar 10, 2020

Study contacts

Pharmacosmos A/S Clinical and Non-clinical Research
study director · Pharmacosmos A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion